Sequoia Financial Advisors LLC Buys New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sequoia Financial Advisors LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,964 shares of the company’s stock, valued at approximately $602,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Contravisory Investment Management Inc. acquired a new position in shares of Medpace during the fourth quarter worth about $26,000. RiverPark Advisors LLC purchased a new stake in shares of Medpace during the fourth quarter worth about $26,000. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Medpace during the fourth quarter worth about $33,000. FinTrust Capital Advisors LLC purchased a new stake in shares of Medpace during the third quarter worth about $30,000. Finally, Altshuler Shaham Ltd purchased a new stake in shares of Medpace during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of analyst reports. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Robert W. Baird lifted their target price on Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $382.00.

Insider Activity

In other news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,340 shares of company stock valued at $76,651,647. 20.30% of the stock is currently owned by insiders.

Medpace Stock Down 0.5 %

Shares of Medpace stock opened at $385.05 on Wednesday. The firm has a market cap of $11.93 billion, a P/E ratio of 43.36, a P/E/G ratio of 2.09 and a beta of 1.38. Medpace Holdings, Inc. has a fifty-two week low of $185.43 and a fifty-two week high of $419.42. The business has a 50-day moving average price of $392.28 and a 200 day moving average price of $318.22.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.24. The firm had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.12 earnings per share. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.